{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:01Z","timestamp":1707524461464},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,21]]},"DOI":"10.7759\/cureus.22433","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T12:08:52Z","timestamp":1645445332000},"source":"Crossref","is-referenced-by-count":0,"title":["A Novel Finding of Lichenoid Drug Reaction From Ibrutinib Therapy"],"prefix":"10.7759","author":[{"given":"Merin","family":"Reji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinchit K","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Cancer Stat Facts. Leukemia \u2014 Chronic Lymphocytic Leukemia (CLL). (2021). Accessed: 1\/29\/2022: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas S","year":"2019","unstructured":"Paydas S. Management of adverse effects\/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019, 136:56-63. 10.1016\/j.critrevonc.2019.02.001","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-019-1534-1","article-title":"Recommendations for ibrutinib treatment in patients with atrial fibrillation and\/or elevated cardiovascular risk","volume":"132","author":"St\u00fchlinger MC","year":"2020","unstructured":"St\u00fchlinger MC, Weltermann A, Staber P, Heintel D, N\u00f6sslinger T, Steurer M. Recommendations for ibrutinib treatment in patients with atrial fibrillation and\/or elevated cardiovascular risk. Wien Klin Wochenschr. 2020, 132:97-109. 10.1007\/s00508-019-1534-1","journal-title":"Wien Klin Wochenschr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-91439-8_7","article-title":"Ibrutinib","volume":"212","author":"Charalambous A","year":"2018","unstructured":"Charalambous A, Schwarzbich MA, Witzens-Harig M. Ibrutinib. Recent Results Cancer Res. 2018, 212:133-68. 10.1007\/978-3-319-91439-8_7","journal-title":"Recent Results Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown JR","year":"2017","unstructured":"Brown JR, Moslehi J, O'Brien S, et al.. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017, 102:1796-805. 10.3324\/haematol.2017.171041","journal-title":"Haematologica"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2701","article-title":"Management of atrial fibrillation in patients on ibrutinib: a Cleveland clinic experience","volume":"10","author":"Khalid S","year":"2018","unstructured":"Khalid S, Yasar S, Khalid A, Spiro TP, Haddad A, Daw H. Management of atrial fibrillation in patients on ibrutinib: a Cleveland clinic experience. Cureus. 2018, 10:e2701. 10.7759\/cureus.2701","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-846808","article-title":"How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia","volume":"133","author":"Stephens DM","year":"2019","unstructured":"Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019, 133:1298-307. 10.1182\/blood-2018-11-846808","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000001745","article-title":"Atypical painful purpuric cutaneous nodules with ibrutinib","volume":"42","author":"Marcaillou M","year":"2020","unstructured":"Marcaillou M, St\u00e9phanie D, Marion B, Julien S, Christophe B. Atypical painful purpuric cutaneous nodules with ibrutinib. Am J Dermatopathol. 2020, 42:1012-4. 10.1097\/DAD.0000000000001745","journal-title":"Am J Dermatopathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5070\/D335c1029x","article-title":"Lichenoid drug eruption","volume":"15","author":"Brauer J","year":"2009","unstructured":"Brauer J, Votava HJ, Meehan S, et al.. Lichenoid drug eruption. Dermatol Online J. 2009, 15:13. 10.5070\/D335c1029x","journal-title":"Dermatol Online J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57090895","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management","volume":"57","author":"Frantz R","year":"2021","unstructured":"Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management. Medicina (Kaunas). 2021, 57:10.3390\/medicina57090895","journal-title":"Medicina (Kaunas)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.IJDVL_353_19","article-title":"Crizotinib-induced oral lichenoid lesions","volume":"86","author":"Sibaud V","year":"2020","unstructured":"Sibaud V, Gomes NP, Raspaud C, Vigarios E. Crizotinib-induced oral lichenoid lesions. Indian J Dermatol Venereol Leprol. 2020, 86:209-11. 10.4103\/ijdvl.IJDVL_353_19","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000412","article-title":"Bruton tyrosine kinase inhibitors: present and future","volume":"25","author":"Burger JA","year":"2019","unstructured":"Burger JA. Bruton tyrosine kinase inhibitors: present and future. Cancer J. 2019, 25:386-93. 10.1097\/PPO.0000000000000412","journal-title":"Cancer J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00512-0","article-title":"Targeting BTK in CLL: beyond ibrutinib","volume":"14","author":"Bond DA","year":"2019","unstructured":"Bond DA, Woyach JA. Targeting BTK in CLL: beyond ibrutinib. Curr Hematol Malig Rep. 2019, 14:197-205. 10.1007\/s11899-019-00512-0","journal-title":"Curr Hematol Malig Rep"},{"key":"ref14","unstructured":"Project Orbis. FDA approves acalabrutinib for CLL and SLL. (2019). Accessed: 2\/14\/2022: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/project-orbis-fda-approves-acalabrutinib-cll-and-sll#:...."},{"key":"ref15","unstructured":"FDA D.I.S.C.O. Burst Edition. FDA approvals of Brukinsa (zanubrutinib), for adult patients with relapsed or refractory marginal zone lymphoma, and Exkivity (mobocertinib) for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations. (2021). Accessed: 2\/14\/2022: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approvals-brukinsa-zanubru...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/78560-a-novel-finding-of-lichenoid-drug-reaction-from-ibrutinib-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:45:58Z","timestamp":1707507958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/78560-a-novel-finding-of-lichenoid-drug-reaction-from-ibrutinib-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.22433","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,21]]}}}